Author

D. T. Evans

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Immunology· 3 Microbiology· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 5 Research Focus:host-pathogen & immune response· 3 Organism:human· 2 Assay:proteomics· 2 Organism:rat· 2 Research Focus:cell type annotation· 1 Research Focus:drug response / drug discovery· 1 Organism:non-human primate· 1

Frequent Co-Authors

A. Finzi· 2 shared D. R. Burton· 2 shared H. M. Gil· 2 shared L. Hangartner· 2 shared N. M. Clark· 2 shared R. Nedellec· 2 shared S. K. Janaka· 2 shared A. B. Ward· 1 shared

Activity by Year

2018-2023 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 36 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersMicrobiology

A. Finzi

Mutual co-authors in cluster

Author profile →

5 papers

Recent·Most cited

Potent antibody-dependent cellular cytotoxicity of a V2-specific antibody is not sufficient for protection of macaques against SIV challenge

M. W. Grunst, H. M. Gil, A. G. Grandea, B. J. Snow, R. Andrabi, R. Nedellec, I. Burton, N. M. Clark, S. K. Janaka, N. K. Keles, R. V. Moriarty, A. M. Weiler, S. Capuano, C. M. Fennessey, T. C. Friedrich, , D. T. Evans

This study shows that potent antibody-dependent cellular cytotoxicity (ADCC) by a V2-specific antibody is insufficient to protect macaques against SIV challenge, but reduced viral loads were observed with a neutralization-sensitive SIV variant.

bioRxiv · Nov 14, 2023Microbiology

MHC class I Ligands of Rhesus Macaque Killer-Cell Immunoglobulin-Like Receptors

J. L. Anderson, K. Sandstrom, W. R. Smith, M. Wetzel, V. A. Klenchin, D. T. Evans

This study identifies MHC class I ligands for rhesus macaque KIRs, revealing novel interactions and functional diversification among these receptors.

bioRxiv · May 25, 2022 · PreprintImmunology

Anti-SARS-CoV-2 IgG and IgA antibodies in COVID-19 convalescent plasma do not facilitate antibody-dependent enhance of viral infection.

N. M. Clark, S. K. Janaka, W. Hartman, S. Stramer, E. Goodhue, J. Weiss, D. T. Evans, J. P. Connor

This study investigates whether antibodies in convalescent plasma enhance SARS-CoV-2 infection and finds no evidence of antibody-dependent enhancement by IgG or IgA isotypes.

bioRxiv · Sep 14, 2021 · PreprintImmunology

Novel compound inhibitors of HIV-1NL4-3 Vpu

C. A. Robinson, T. D. Lyddon, H. M. Gil, D. T. Evans, Y. V. Kuzmichev, J. Richard, A. Finzi, S. Welbourn, L. Rasmussen, N. M. Nebane, V. V. Gupta, S. Ananthan, Z. Cai, E. R. Wonderlich, C. Augelli-Szafran, , M. C. Johnson

This study identifies two compounds that inhibit HIV-1NL4-3 Vpu activity but are strain-specific.

bioRxiv · Jul 30, 2021Microbiology

Vaccine-induced protection from homologous Tier 2 simian-human immunodeficiency virus challenge in nonhuman primates

M. G. Pauthner, J. P. Nkolola, C. Havenar-Daughton, B. Murrell, S. M. Reiss, R. Bastidas, J. Prevost, R. Nedellec, B. von Bredow, P. Abbink, C. A. Cottrell, D. W. Kulp, T. Tokatlian, B. Nogal, M. Bianchi, , D. R. Burton

This study shows that high serum neutralizing antibody titers from Env protein vaccination protect rhesus macaques from Tier 2 SHIV challenge, with ~1:500 ID50 titers providing over 90% protection.

bioRxiv · Oct 29, 2018Immunology